



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study

Melbourne (Australia)– 14th May 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') today announces that it has been granted a Type B pre-IND meeting with the United States Food and Drug Administration (FDA) in relation to the Company's planned Phase III ProstACT trial for TLX591 (¹⁷⁷Lu-DOTA-rosopitamab) for the treatment of metastatic castrate-resistant prostate cancer. The meeting date has been scheduled for the 7th July, 2020.

The company's planned Phase III ProstACT trial is a second-line study in men with metastatic castrate-resistant prostate cancer whose disease has progressed following initial treatment. The study will examine the effectiveness of TLX591 in combination with best standard care, compared with best standard care alone. The trial will recruit patients primarily in Australia and the United States, subject to regulatory approvals to conduct the study.

Telix CEO Dr Chris Behrenbruch said that "The Company has spent many months preparing for this meeting request and once we have feedback from the Agency on our planned clinical activity, we will be providing a comprehensive update to Shareholders on the future development strategy for this asset. Our preparation for this meeting and the design of the ProstACT trial has been conducted in close consultation with an advisory board comprising leading US, European and Australian urologic oncology experts and trialists".

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.